Creative Biolabs provides AAV capsid screening services to identify and prioritize vectors for CNS gene-delivery studies, including blood-brain barrier access, neural cell tropism, regional distribution, route-of-administration comparisons, and peripheral detargeting. Support can be configured across capsid-library strategy, experimental selection, sequencing-based enrichment analysis, individual-candidate validation, biodistribution assessment, and collaborative study interpretation.
Selection should follow the biological question
The AAV capsid influences receptor engagement, tissue access, cellular uptake, intracellular trafficking, and the distribution of vector genomes after administration. For CNS programs, a useful candidate must be evaluated in the context of the intended route, species, age, target region, target cell population, and expression cassette rather than selected from serotype reputation alone.
Systemic, cerebrospinal-fluid, and intraparenchymal delivery impose different selection pressures. A screen can therefore be designed to enrich for a desired phenotype while monitoring counter-selection criteria such as peripheral biodistribution, nonspecific cell entry, or strong recovery without productive transduction.
Modular experimental support
Modules can be combined into a discovery-to-validation program or used to answer a defined comparison question with supplied capsids.
Study planning may cover natural-serotype panels, defined engineered variants, peptide-insertion libraries, mutational neighborhoods, or barcoded candidate pools. Library composition and controls are aligned with the intended selection pressure and downstream recovery method.
Candidate evaluation can be structured around relevant cells, co-cultures, barrier models, neural cultures, or tissue preparations when these systems fit the biological objective. Assays may distinguish binding, uptake, genome delivery, and expression endpoints.
For suitable research programs, pooled selection can be planned around route, target tissue, sampling scheme, comparator capsids, and recovery endpoint. Species and study design are selected with careful attention to biological relevance and known translation limits.
Sequencing-based workflows can compare input and recovered variant abundance, assess replicate behavior, calculate enrichment, and rank candidates across target and off-target samples. Analysis criteria are documented before candidates advance.
Shortlisted variants can be evaluated individually against parental or benchmark capsids. Validation may include vector-genome distribution, reporter expression, immunostaining, cell-type colocalization, and quantitative tissue analysis as appropriate.
Target-tissue performance can be interpreted alongside peripheral-organ recovery or expression. This paired view helps distinguish broad exposure from useful CNS access and supports evidence-based candidate prioritization.
Recovery of a capsid sequence is not always equivalent to productive gene expression. A robust program pairs the selection event with the biological outcome that matters.
| Research question | Useful screen readout | Candidate-confirmation readout |
|---|---|---|
| Does the capsid reach CNS tissue? | Variant DNA recovery and enrichment across CNS regions | Vector-genome biodistribution with peripheral comparators |
| Is delivery productive? | RNA-based recovery or reporter-linked selection | Transgene RNA, protein, or reporter quantification |
| Which cells are transduced? | Cell-enriched recovery or cell-type-restricted expression | Marker colocalization, imaging, or cell-resolved analysis |
| Is peripheral exposure reduced? | Counter-selection or target-to-off-target enrichment | Matched CNS and peripheral-tissue assessment |
Stage-gated and decision-ready
Each stage produces information used to refine the next, reducing the chance that a high-ranking sequence advances without an appropriate biological check.
Clarify route, species, anatomical target, cell population, payload constraints, comparators, and off-target concerns.
Select an appropriate capsid panel or library architecture, define controls, and establish recovery and ranking rules.
Generate the screening material and evaluate representation or other study-relevant quality attributes before selection.
Apply the agreed experimental pressure in the selected model and collect predefined target and comparator samples.
Quantify variant abundance, calculate enrichment, review replicate consistency, and compare on-target and off-target behavior.
Produce shortlisted capsids separately and test them against the benchmark under matched conditions.
Resolve distribution, expression, anatomical coverage, and cell-type association with fit-for-purpose assays.
Deliver methods, results, interpretation, limitations, and a prioritized candidate set for the next study phase.
Prioritize candidates for brain or spinal-cord delivery after vascular administration while tracking peripheral distribution.
Compare delivery to neurons, astrocytes, oligodendrocytes, microglia, endothelial cells, or other defined populations.
Evaluate candidates for distribution within selected brain regions or spinal anatomy after local or CSF-directed delivery.
Assess capsid behavior in a research context where pathology, age, inflammation, or tissue remodeling may alter access and transduction.
Compare systemic, CSF, or local administration strategies using a shared endpoint framework and benchmark panel.
Rank candidates by desired CNS delivery together with reduced recovery or expression in specified peripheral tissues.
Usable outputs at every stage
The final package is scoped to the work performed and can support internal candidate review, follow-on validation, or transfer into a broader vector-development program.
Benchmark a defined set of natural or engineered capsids in a selected CNS model.
Screen a broader library, recover enriched variants, and nominate candidates for confirmation.
Test user-supplied or previously selected capsids with orthogonal expression and biodistribution endpoints.
Connect capsid screening with vector design, preparation, delivery, and downstream CNS analysis.
The screen is anchored to the delivery phenotype and counter-selection criteria that matter to the program.
High-throughput discovery is followed by matched testing of separate candidates before advancement.
Genome recovery, expression, histology, and distribution can be combined to reduce misleading rankings.
Methods, controls, limitations, and decision rules are documented for informed internal review.
Fill out the form below, and our expert team will contact you to design your custom project and accelerate breakthrough innovations.
